Charles Grob M.D.
Psilocybin At The End Of Life
Charles Grob MD is professor of Psychiatry and Pediatrics at the UCLA School of Medicine and Director of the Division of Child and Adolescent Psychiatry at Harbor-UCLA Medical Center.
His work includes a pilot research investigation conducted at Harbor-UCLA Medical Center and the Los Angeles BioMedical Research Institute examining the safety and efficacy of psilocybin treatment in patients with advanced-stage cancer anxiety. This study, funded by the Heffter Research Institute, was the first formal effort in several decades designed to re-examine early promising findings using a psychedelic treatment model to address the psychospiritual demoralization often encountered by individuals with terminal cancer.
Charles S. Grob, M.D. is Director of the Division of Child and Adolescent Psychiatry at Harbor-UCLA Medical Center, and Professor of Psychiatry and Pediatrics at the UCLA School of Medicine. Dr. Grob conducted the first government approved psychobiological research study of MDMA, and was the principal investigator of an international research project in the Brazilian Amazon studying the visionary plant brew, ayahuasca. He has also completed and published the first approved research investigation in several decades on the safety and efficacy of psilocybin treatment in terminal cancer patients with anxiety. And, he has recently completed a pilot investigation into the use of an MDMA treatment model for social anxiety in autistic adults. Dr. Grob is the editor of Hallucinogens: A Reader (Tarcher/Putnam, 2002) and co-editor (with Roger Walsh) of Higher Wisdom: Eminent Elders Explore the Continuing Impact of Psychedelics (SUNY Press, 2005). He is also a founding board member of the Heffter Research Institute.